A Study of AK112 for Advanced Solid Tumors
A Phase I/II Trial of AK112 in Advanced Solid Tumor
Sponsor: Akeso
Listed as NCT04597541, this PHASE1/PHASE2 trial focuses on Solid Tumor, Adult and remains completed. Sponsored by Akeso, it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Nov 2024 — Apr 2025 [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akeso
For direct contact, visit the study record on ClinicalTrials.gov .